UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
(
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e) On October 10, 2020, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Albireo Pharma, Inc. (the “Company”) approved the grant of two contingent cash incentive awards of $100,000 to Martha Carter, Chief Regulatory Officer of the Company, and Patrick T. Horn, M.D., Ph.D., Chief Medical Officer of the Company. Ms. Carter and Dr. Horn will each receive (1) $50,000 if the Company submits to the Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”), whichever comes first, an application for approval of the Company’s product candidate, odevixibat, in patients with progressive familial intrahepatic cholestasis by a specified date, and (2) an additional $50,000 if such application is approved by the FDA or the EMA, whichever comes first, prior to a specified date, in each case subject to Ms. Carter and Dr. Horn remaining employed and in good standing by the Company at the time of payment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALBIREO PHARMA, INC. | |
| Date: October 15, 2020 | /s/ Ronald H.W. Cooper |
| Ronald H.W. Cooper | |
| President and Chief Executive Officer |
Cover |
Oct. 10, 2020 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Oct. 10, 2020 |
| Entity File Number | 001-33451 |
| Entity Registrant Name | ALBIREO PHARMA, INC. |
| Entity Central Index Key | 0001322505 |
| Entity Tax Identification Number | 90-0136863 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 10 Post Office Square |
| Entity Address, Address Line Two | Suite 1000 |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02109 |
| City Area Code | 857 |
| Local Phone Number | 254-5555 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock |
| Trading Symbol | ALBO |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |